Issue of Equity
21 5월 2008 - 11:12PM
UK Regulatory
RNS Number : 9971U
Amarin Corporation Plc
21 May 2008
AMARIN MAKES APPLICATION FOR THE ADMISSION OF ORDINARY SHARES
DUBLIN, Ireland, May 21, 2008 Amarin Corporation plc (NASDAQ: AMRN) (the "Company") has made an application to the London Stock Exchange
and the Irish Stock Exchange in respect of 869,565 ordinary shares of £0.50 each ("Ordinary Shares") in the capital of the Company to be
admitted to trading on AIM and IEX respectively. The Ordinary Shares are to be issued in connection with Amarin's recently announced
private placement of equity.
About Amarin
Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous
system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease,
epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of
molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary
stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").
Contacts:
Amarin +353 (0)1 669 9020
Thomas Lynch, Chairman and Chief Executive Officer
Alan Cooke, President and Chief Operating Officer
Darren Cunningham, EVP Strategic Development and Investor Relations
investor.relations@amarincorp.com
Investors:
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields +1 212 838 3777
Bruce Voss +1 310 691 7100
Media:
Powerscourt +44 (0) 207 250 1446
Rory Godson
Paul Durman
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOESEUFLFSASESI
Amarin (LSE:AMRN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Amarin (LSE:AMRN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
Amarin Corp (런던증권거래소)의 실시간 뉴스: 최근 기사 0
More Amarin Corporation News Articles